🇺🇸 FDA

Intelligence · Patents

Recently granted patents

New US pharmaceutical patent grants from the past 12 months — competitive surveillance for BD and IP teams.

Patents
632

Quick answer

632 pharmaceutical patents in our USPTO index were granted within the past year. Browse by grant date with links to applicant company portfolios and related drug profiles.

  1. US 12398194

    Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface

    AUTOLUS LIMITED · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12398193

    Targeted replacement of endogenous T cell receptors

    The Regents of the University of California · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12398140

    Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12396989

    Nicorandil derivatives

    UNICYCIVE THERAPEUTICS, INC. · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12396994

    Compositions for improving physiological function with age

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12397013

    Extrahepatic delivery

    Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12397034

    Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons

    China Medical University · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12398197

    Antibodies with engineered CH2 domains, compositions thereof and methods of using the same

    Sutro Biopharma, Inc. · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12396949

    Technology for improving properties of lipid nanoparticles using lipids in which cis-unsaturated bonds are substituted with a silicon atom

    The Regents of the University of California · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12397028

    Adoptive cellular therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12391732

    Articles comprising a silk polypeptide for antigen delivery

    Ludwig-Maximilians-Universitat Munchen · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12391760

    Method of treating primary sclerosing cholangitis

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12390496

    Methods for treating ulcerative colitis

    Finch Therapeutics Holdings LLC · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12391739

    Method for producing gamma delta T cells

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12391765

    Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12391658

    Sulfoxide and sulfone glucokinase activators and methods of use thereof

    VTV THERAPEUTICS LLC · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12391750

    Anti-C1S antibodies and methods of use thereof

    Bioverativ USA Inc. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12391720

    Salts and polymorphs of cethromycin for the treatment of disease

    AliquantumRx, Inc. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12390497

    Microbial strains for virus inhibition

    MICROBIAL DISCOVERY GROUP, LLC · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12391742

    Anti-KRAS-G12D T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12391642

    Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12390524

    Compositions and methods for inducing immune responses

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12390453

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12391643

    Substituted amino-thiol and amino-disulfide compounds, and uses thereof

    The Regents of the University of California · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12390509

    Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof

    Larimar Therapeutics, Inc. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12390483

    Compounds and methods for treating neurological and cardiovascular conditions

    The Board of Regents of the University of Texas System · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12390427

    Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12391753

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12390512

    Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae

    SHANGHAI REINOVAX BIOLOGICS CO., LTD · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12391923

    SIRPα-silenced natural killer (NK) cells

    The Regents of the University of California · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12391654

    CFTR regulators and methods of use thereof

    The Regents of the University of California · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12390462

    Muscarinic acetylcholine M1 receptor antagonists

    Contineum Therapeutics, Inc. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12390463

    Dosage forms and regimens for amino acid compounds

    Pliant Therapeutics, Inc. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12390473

    Methods of treating tyrosine kinase inhibitor-induced diarrhea

    The Regents of the University of California · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12391669

    Substituted pyrimidines as IRE1 kinase inhibitors

    The Regents of the University of California et al. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12391920

    Models of tauopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12389889

    Mouse having a humanized cluster of differentiation 47 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12391686

    Compounds and uses thereof

    FOGHORN THERAPEUTICS INC. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12391663

    Isoindolinone compounds

    Monte Rosa Therapeutics AG · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12389931

    Oyster peptide with effect of improving sexual function and preparation method thereof

    CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES CO., LTD. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12391741

    T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof

    MiNK Therapeutics, Inc. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12390419

    Formulations of (R)-2-amino-3-phenylpropyl carbamate

    AXSOME MALTA LTD. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12391734

    PD-1 homing endonuclease variants, compositions, and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12383566

    Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity

    Northwestern University · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12384775

    Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12384779

    Bicyclic compounds

    Aligos Therapeutics, Inc. · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12383567

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How recent are these patent grants?

This hub lists published patents with a grant date within the last 365 days, ordered newest first.

Which patent classes are included?

We index USPTO PatentsView records with pharmaceutical CPC classifications A61K and A61P linked to tracked assignee companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.